Clinical trial Recruiting at 7 sites Interventional Ages 13 and up

How subcortical arousal affects perception

Official title: Shared Subcortical Arousal Systems Across Perceptual Modalities

Run by Yale University · NCT06934356 · Data updated 2026-11-12

This study will test whether activity in deep arousal circuits changes how healthy adults and people with epilepsy (who have thalamic electrodes) perceive sights, sounds, and touch using fMRI, eye measurements, behavioral tests, and direct thalamic recordings and stimulation.

Quick facts

Study typeInterventional
Ages13 Years and up
SexAll
Enrollment202 (estimated)
SponsorYale University
Academic / other
Locations8 sites (New Haven, Connecticut and 7 other locations)
StatusRecruiting
StartedOctober 13, 2025
Main results expectedDecember 2030
Study endsDecember 2030
Registry record updatedAugust 10, 2026
Trial IDNCT06934356 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal participants are adults with normal vision and hearing for the healthy cohort (age 18+), and adolescents or adults with epilepsy who already have clinically placed thalamic electrodes (age 13+) for the patient cohort.

Probably not a fit

People without normal vision or hearing for accurate eye metrics, pregnant individuals, those with nonremovable ferromagnetic implants (preventing MRI), or people without thalamic electrodes are unlikely to receive direct clinical benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The project combines fMRI, eye-tracking (pupil and gaze), behavioral tasks, and direct thalamic recording/stimulation to study how shared subcortical arousal systems influence visual, auditory, and tactile perception. Healthy adult participants will undergo fMRI and eye-metric testing across replicated sessions (auditory and tactile cohorts, N=65 each) and the team will use an existing visual dataset (N=65) for comparison. Analyses will compare brain and eye-metric signatures for perceived versus not-perceived stimuli and will apply machine-learning classification of eye metrics to identify report-independent markers of perception. A separate patient cohort with epilepsy and implanted thalamic electrodes will undergo direct recording and stimulation alongside eye and behavioral measures at participating epilepsy centers.

Why it matters

Potential benefit: If successful, the work could improve understanding of how deep arousal circuits shape perception and point toward better monitoring or targeted interventions for perceptual problems in epilepsy.

How similar studies have gone: Prior fMRI work from this group (including Kronemer et al., 2022) showed robust subcortical signals linked to visual perception, but combining cross-modal fMRI, eye-metric machine-learning, and direct thalamic recording/stimulation across modalities is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
A. The following are the inclusion/exclusion criteria for healthy participants age 18 years and up (Aim 1 and 2):

Inclusion: (1) normal vision with or without the use of corrective lenses; (2) normal hearing not needing an assistive hearing device.

Exclusion: (1) past history of diagnosis of a psychiatric or neurologic disease; (2) current psychiatric or neurologic disease; (3) requires hard contact lenses or glasses to maintain normal vision (prevents accurate pupil and eye gaze measurements); (4) pregnant or nonremovable ferrous metal objects inside or on the body (prevents MRI).

B. The following are the inclusion/exclusion criteria for epilepsy patients with thalamic electrodes age 13 years and up (Aim 3A):

Inclusion: (1) normal vision with or without the use of corrective lenses

Exclusion: (1) severe vision impairment even with correction preventing ability to see stimuli (prevents accurate pupil and eye gaze measurements); (2) unable to perform the perception task due to cognitive impairment. All participants must be capable of consenting for themselves.

C. The following are the inclusion/exclusion criteria for epilepsy patients with thalamic electrodes age 18 year and up (Aim 3B):

Inclusion: (1) normal vision with or without the use of corrective lenses; (2) A female subject must have a negative pregnancy test and if sexually active, must be using a reliable form of birth control for the duration of the trial, be surgically sterile, or be at least two years post-menopausal.

Exclusion: (1) severe vision impairment even with correction preventing ability to see stimuli (prevents accurate pupil and eye gaze measurements); (2) unable to perform the perception task due to cognitive impairment. All participants must be capable of consenting for themselves; (3) Pregnancy.

Where it's running

  • Yale School of Medicine
    New Haven, Connecticut, United States
    Recruiting
  • University of Kansas Medical Center
    Kansas City, Kansas, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts, United States
    Recruiting
  • Mayo Clinic
    Rochester, Minnesota, United States
    Recruiting
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire, United States
    Recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee, United States
    Recruiting
Show 2 more locations
  • Baylor College of Medicine
    Houston, Texas, United States
    Recruiting
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania, United States
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.